Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 14/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294774 | 1.00 | CMA1 (0.40) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL1294649 | 0.87 | MGAM (0.34) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL1294646 | 0.87 | MGAM (0.34) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL2312681 | 0.87 | SLC6A2 (0.36) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL2314034 | 0.87 | GAA (0.40) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL1294671 | 0.86 | CMA1 (0.43) | CMA1 | |
| SCHEMBL1294666 | 0.86 | CMA1 (0.43) | CMA1 | |
| SCHEMBL2311580 | 0.85 | CTSA (0.36) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL2314344 | 0.85 | GAA (0.39) | CMA1SLC6A2MGAMGAASI | |
| SCHEMBL2314336 | 0.85 | GAA (0.39) | CMA1SLC6A2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062056-B2 | Aza-benzimidazolone Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2364313-B1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-20110269780-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2364313-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010030500-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269780-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885SLC6A2 4245/4885MGAM 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.